[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 281
6. Militerno G, Bazzo R, Marcato PS: Cytological diagnosis of mandibular salivary gland adenocarcinoma in a dog. J Vet Med A Physiol Pathol Clin Med; 2005 Dec;52(10):514-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of mandibular salivary gland adenocarcinoma in a dog.
  • A case of mandibular salivary gland adenocarcinoma in a 9-year-old female dog is described.
  • Material collected by fine needle aspiration underwent cytological examination and after the diagnosis of salivary carcinoma the mass was surgically excised and then was processed for histological examination.
  • The aim of this work is to describe the cytopathological features of this carcinoma and to emphasize the usefulness of fine needle aspiration technique, which is an effective, inexpensive and minimally invasive method of diagnosis that can be performed before incisional biopsy or even before surgical excision.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / pathology. Salivary Gland Neoplasms / veterinary
  • [MeSH-minor] Animals. Biopsy, Fine-Needle / veterinary. Diagnosis, Differential. Dogs. Female

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300660.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Park JH, Moon YH, Kim DJ, Kim SA, Lee JB, Ahn SG, Yoon JH: Photodynamic therapy with hexenyl ester of 5-aminolevulinic acid induces necrotic cell death in salivary gland adenocarcinoma cells. Oncol Rep; 2010 Jul;24(1):177-81
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with hexenyl ester of 5-aminolevulinic acid induces necrotic cell death in salivary gland adenocarcinoma cells.
  • The aim of this study was to examine whether PDT with hexenyl ester of 5-aminolaevulinic acid (ALA-hx) inhibits the proliferation of the salivary gland adenocarcinoma SGT cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Photochemotherapy. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514459.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reactive Oxygen Species; 88755TAZ87 / Aminolevulinic Acid; EC 1.3.3.3 / Coproporphyrinogen Oxidase; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


8. Yoon JH, Kim SA, Kwon SM, Park JH, Park HS, Kim YC, Yoon JH, Ahn SG: 5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling. Biochim Biophys Acta; 2010 Mar;1800(3):352-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling.
  • METHODS: Human salivary gland adenocarcinoma (SGT) cells were used in this study.
  • Thus, 5'-NIO could be used as a candidate for salivary gland adenocarcinoma therapeutics.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / drug effects. Cell Cycle / drug effects. Indoles / pharmacology. Oximes / pharmacology. Receptor, Notch1 / genetics. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19914349.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 5'-nitroindirubinoxime; 0 / DNA Primers; 0 / Indoles; 0 / NOTCH1 protein, human; 0 / Oximes; 0 / Receptor, Notch1
  •  go-up   go-down


9. Park JH, Yoon JH, Kim SA, Ahn SG, Yoon JH: (-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells. Oncol Rep; 2010 Feb;23(2):585-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells.
  • EGCG has been found to induce apoptosis in salivary gland carcinoma cells, however, it is not known whether EGCG affects invasion and migration.
  • Thus, this study was performed to clarify whether EGCG affects invasion and migration of salivary gland tumors.
  • These results indicate that EGCG may effectively suppress salivary gland tumors by inhibiting metastasis through beta1 integrin-mediated signaling.
  • [MeSH-major] Adenocarcinoma / pathology. Catechin / analogs & derivatives. Cell Movement / drug effects. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043125.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antigens, CD29; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


10. Yoon JH, Kim SA, Kim JI, Park JH, Ahn SG, Yoon JH: Inhibition of invasion and migration of salivary gland adenocarcinoma cells by 5'-nitro-indirubinoxime (5'-NIO). Head Neck; 2010 May;32(5):619-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of invasion and migration of salivary gland adenocarcinoma cells by 5'-nitro-indirubinoxime (5'-NIO).
  • The present study investigated the anti-invasive action of 5'-NIO in salivary gland ductal adenocarcinoma, SGT cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Movement / drug effects. Indoles / pharmacology. Oximes / pharmacology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827125.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5'-nitroindirubinoxime; 0 / Antigens, CD29; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Oximes; 0 / RNA, Messenger; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


11. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M, Furusawa K: Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol; 2007 Feb;30(2):393-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.
  • For in vitro and in vivo chemotherapeutic studies, we used the following head and neck cancer cell lines: a mouse oral squamous cell carcinoma (SCC) cell line, Sq-1979; a human SCC cell line, SCCHA; a mouse salivary gland adenocarcinoma (SGA) cell line, NR-PG; and a human SGA cell line, HSY.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Multidrug Resistance-Associated Proteins / biosynthesis. Salivary Gland Neoplasms / drug therapy. Taxoids / pharmacology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203221.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCC10 protein, human; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / Taxoids; 15H5577CQD / docetaxel; 1806-98-0 / estradiol-17 beta-glucuronide; 4TI98Z838E / Estradiol
  •  go-up   go-down


12. Basile JR, Lin YL: A salivary gland adenocarcinoma mimicking a microcystic adnexal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):e28-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A salivary gland adenocarcinoma mimicking a microcystic adnexal carcinoma.
  • We describe a salivary gland adenocarcinoma arising in the lower lip, characterized by ductal structures and cords, 3-5 cell layers in thickness, set in a dense fibrous stroma and also invading nerves, thus mimicking a MAC in both its clinical and its histopathologic appearance.
  • The diagnostic dilemma presented by this lesion is discussed, along with a differential diagnosis and brief review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Skin Appendage / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Biopsy. Cell Nucleus / ultrastructure. Cell Proliferation. Connective Tissue / pathology. Cytoplasm / ultrastructure. Diagnosis, Differential. Female. Fibrosis. Humans. Lip / innervation. Middle Aged. Neoplasm Invasiveness. Sclerosis

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [CommentIn] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Sep;112(3):284-6 [21684772.001]
  • (PMID = 20303043.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


13. Stenner M, Weinell A, Ponert T, Hardt A, Hahn M, Preuss SF, Guntinas-Lichius O, Klussmann JP: Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. Histopathology; 2010 Nov;57(5):699-706
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer.
  • The aim was to assess its expression and prognostic value in salivary gland adenocarcinoma and muco-epidermoid carcinoma.
  • METHODS AND RESULTS: Survivin expression was analysed in 48 patients with parotid gland cancer (21 muco-epidermoid, 27 adenocarcinomas) by means of immunohistochemistry.
  • CONCLUSIONS: The correlation between cytoplasmic survivin expression and survival in salivary gland malignancies might make this an effective tool in patient follow-up, prognosis and targeted therapy in future.
  • [MeSH-major] Cytoplasm / metabolism. Microtubule-Associated Proteins / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21083600.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


1
Advertisement
4. Ferrazzo KL, Alves SM Jr, Santos E, Martins MT, de Sousa SM: Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. Oral Oncol; 2007 Jul;43(6):580-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.
  • Adenoid cystic carcinoma (ACC) and polymorphous low-grade adenocarcinoma (PLGA) are malignant neoplasms of salivary glands, which are similar in histologic patterns but very different in clinical behavior, treatment and prognosis.
  • Moreover, slides of normal salivary glands were included.
  • In normal salivary glands there was strong nuclear and cytoplasmic staining for galectin-3 in ductal luminal cells.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Galectin 3 / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996782.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


15. Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F: Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer; 2006 Jul 15;119(2):441-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
  • We developed and characterized a HER2/neu and Fas overexpressing cell line (BNT.888 ACA2) from a salivary gland adenocarcinoma that arose in a HER2/neu transgenic mouse.
  • [MeSH-major] Antigens, CD95 / metabolism. Antineoplastic Agents / pharmacology. Carcinoma, Acinar Cell / drug therapy. Neoplasm Proteins / drug effects. Quinazolines / pharmacology. Receptor, ErbB-2 / metabolism. Salivary Gland Neoplasms / drug therapy


16. Jaehne M, Dippel A, Sagowski C: [Salivary duct carcinoma of the submandibular gland]. HNO; 2005 Nov;53(11):940-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salivary duct carcinoma of the submandibular gland].
  • [Transliterated title] Speichelgangkarzinome der Glandula submandibularis.
  • BACKGROUND: Salivary duct carcinoma (SDC) is a rare adenocarcinoma of the salivary glands which usually occurs in the parotid gland (approx.
  • 80%), but is also found in the submandibular gland (approx.
  • 12%) and the minor salivary glands.
  • Due to the low incidence of this tumour-particularly in terms of involvement of the submandibular and minor salivary glands-only limited clinical data is available.
  • PATIENTS/METHOD: In a retrospective investigation, follow-ups of six patients with a SDC of the submandibular gland were analysed and the surgical measures evaluated for their efficiency.
  • RESULTS: At the time of diagnosis, varying tumor stages were present (2xT1, 3xT2, 1xT1).
  • In all patients, the submandibular gland was resected and neck dissection performed, in two cases (33,3%) this was followed by radiotherapy.
  • CONCLUSION: The clinical course of patients with SDC of the submandibular gland exhibits a high (66.6%) rate of local recurrence, crucial for the following clinical course.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Ducts. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Submandibular Gland / pathology. Submandibular Gland / surgery. Survival Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1994 Jan;172(1):35-44 [7931825.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):561-6 [8666365.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2 Suppl 3):19-23 [10810934.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):223-30 [8625227.001]
  • [Cites] Tumori. 1996 Sep-Oct;82(5):502-4 [9063535.001]
  • [Cites] Head Neck. 2002 Apr;24(4):406-10 [11933184.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):275-7 [8776426.001]
  • [Cites] Virchows Arch. 1996 May;428(2):75-83 [8925128.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jul;78(1):74-80 [7915829.001]
  • [Cites] J Laryngol Otol. 1986 Jan;100(1):105-14 [3944499.001]
  • [Cites] Diagn Cytopathol. 1999 Oct;21(4):271-5 [10495321.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1503-12 [7688652.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5675-82 [7522962.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):958-67 [8780532.001]
  • [Cites] Head Neck. 1997 Mar;19(2):126-33 [9059870.001]
  • [Cites] Acta Cytol. 1985 May-Jun;29(3):454-6 [2988249.001]
  • [Cites] Laryngorhinootologie. 2001 Sep;80(9):525-9 [11555785.001]
  • (PMID = 15678343.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Alvarez Marcos CA, Méndez Alvarez JR, Domínguez Iglesias F, Hevia Llamas R, Fernández Espina H, Junco Petrement P: [Unusual cervical cyst. Adenocarcinoma ex-pleomorphic adenoma of a minor salivary gland]. Acta Otorrinolaringol Esp; 2006 Nov;57(9):429-31
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual cervical cyst. Adenocarcinoma ex-pleomorphic adenoma of a minor salivary gland].
  • [Transliterated title] Quiste cervical inusual. adenocarcinoma ex-adenoma pleomorfo de glándula salival menor.
  • It is even more uncommon that the malignant tumour has its origin in a minor salivary gland as it is the malignant transformation of a pleomorphic adenoma.
  • Some considerations are made regarding its localization, histopathology, diagnosis and therapeuthic attitude, as well as some advices to take into account in order to arrive to the diagnosis and correct treatment in similar cases to the one shown.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Head and Neck Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184013.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Ferrazzo KL, Neto MM, dos Santos E, dos Santos Pinto D, de Sousa SO: Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. J Oral Pathol Med; 2009 Oct;38(9):701-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.
  • BACKGROUND: Galectin-3 has been implicated in tumor progression of some malignancies as thyroid, prostate, and salivary gland tumors.
  • Thus, the present study aimed to correlate galectin-3 expression with beta-catenin and cyclin D1 expressions in adenoid cystic carcinoma (ACC) and in polymorphous low-grade adenocarcinoma (PLGA).
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenoid Cystic / metabolism. Cyclin D1 / biosynthesis. Galectin 3 / biosynthesis. Salivary Gland Neoplasms / metabolism. beta Catenin / biosynthesis


19. Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ: The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):826-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac.
  • STUDY DESIGN: The expression and functional role of Stat3 and survivin was evaluated in 2 salivary gland adenocarcinoma cell lines (HSY and HSG).
  • CONCLUSIONS: Taken together, these data support the importance of the constitutive Stat3 signaling for growth and survival of salivary gland cancer cells through the induction of survivin.
  • Inhibition of the oncogenic Stat3-survivin pathway in these cells can be achieved by selective targeting techniques or treatment with the NSAID sulindac and holds promise for the treatment of salivary gland cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents / pharmacology. Cyclooxygenase Inhibitors / pharmacology. Microtubule-Associated Proteins / metabolism. STAT3 Transcription Factor / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Dec;118(6):746 [25610927.001]
  • (PMID = 19272804.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE12606; United States / NIDCR NIH HHS / DE / DE13118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclooxygenase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 184SNS8VUH / Sulindac
  •  go-up   go-down


20. Asioli S, Marucci G, Ficarra G, Stephens M, Foschini MP, Ellis IO, Eusebi V: Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch; 2006 Jan;448(1):29-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous adenocarcinoma of the breast. Report of three cases.
  • We report three cases of polymorphous adenocarcinoma (PLA) of the breast in 37-, 55- and 74-year-old women, respectively.
  • The tumours consist of monotonous cells showing a wide spectrum of growth patterns: solid nests, trabeculae, tubules, cribriform structures, strands and fascicles reminiscent of polymorphous low-grade adenocarcinoma of salivary glands.
  • To our knowledge, PLA has never been reported in the breast; therefore, this tumour should be added to the list of neoplastic lesions of the breasts that have the same features as those of the salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1984 Apr;81(4):436-41 [6702745.001]
  • [Cites] Histopathology. 1994 Jul;25(1):31-9 [7959643.001]
  • [Cites] Virchows Arch. 2004 Jan;444(1):13-9 [14634807.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Aug;56(2):157-66 [6578478.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):248-58 [8434705.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):497-506 [12835294.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):303-10 [9565338.001]
  • [Cites] Semin Diagn Pathol. 1989 May;6(2):174-88 [2503862.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Histopathology. 2002 Sep;41(3):250-9 [12207787.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):74-81 [10963383.001]
  • [Cites] Semin Diagn Pathol. 1989 May;6(2):153-64 [2474845.001]
  • [Cites] Histopathology. 1987 Mar;11(3):305-15 [2828217.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):641-5 [12167416.001]
  • [Cites] Histopathology. 1977 Jul;1(4):301-14 [355082.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):287-92 [15306944.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):913-21 [1698339.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):935-42 [6692293.001]
  • [Cites] Arch Ophthalmol. 2004 Jun;122(6):915-7 [15197069.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):695-700 [16075292.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1319-28 [11023093.001]
  • [Cites] Histopathology. 2004 Feb;44(2):164-71 [14764060.001]
  • [Cites] Virchows Arch. 2005 Feb;446(2):142-9 [15583933.001]
  • [Cites] Int J Surg Pathol. 2003 Jan;11(1):43-9 [12598921.001]
  • (PMID = 16220292.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


21. McHugh JB, Visscher DW, Barnes EL: Update on selected salivary gland neoplasms. Arch Pathol Lab Med; 2009 Nov;133(11):1763-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on selected salivary gland neoplasms.
  • CONTEXT: Malignancies of the salivary gland are uncommon and account for 0.3% of all malignancies.
  • OBJECTIVE: To provide an overview of 4 salivary gland malignancies that we often see in consultation, with a focus on essential diagnostic features and the importance of reporting pertinent diagnostic information to ensure appropriate clinical management.
  • Polymorphous low-grade adenocarcinoma can be a challenging diagnosis on biopsy specimens.
  • Evaluation of the tumor periphery and nuclear features should lead to the correct diagnosis in most cases.
  • Salivary duct carcinoma is an aggressive malignancy characterized by histologic resemblance to breast carcinoma, high-grade cytologic features, and expression of androgen receptor.
  • Benign and malignant myoepithelial neoplasms have a broad morphologic spectrum, and immunohistochemistry is important in reaching the correct diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Carcinoma in Situ / diagnosis. Carcinosarcoma / diagnosis. Salivary Gland Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Salivary Ducts / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886710.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Moreno M, Moreno A, Tomé C: Sentinel lymph node biopsy in adenocarcinoma of minor salivary gland. Oral Oncol; 2008 Mar;44(3):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy in adenocarcinoma of minor salivary gland.
  • Adenocarcinoma of the minor salivary gland (MSG) is a rare neoplasm.
  • Microscopically, the neoplasms classified as adenocarcinoma not otherwise specified (NOS) are a histologically heterogeneous group: they vary from highly anaplastic adenocarcinoma to moderate and well-differentiated lesions.
  • This report describes a case of adenocarcinoma of MSG occurring in the buccal mucosa of a 24-year-old male.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Glands, Minor / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17467330.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Darling MR, Gauthier M, Jackson-Boeters L, Daley TD, Chambers AF, Tuck AB: Osteopontin expression in salivary gland tumours. Oral Oncol; 2006 Apr;42(4):363-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression in salivary gland tumours.
  • This study examines by immunohistochemistry the expression of OPN in normal salivary gland tissue and three types of salivary gland tumour: pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC) and polymorphous low grade adenocarcinoma (PLGA).
  • PAs and PLGAs demonstrated higher levels of OPN than normal salivary gland tissue, while ACC, although showing a trend towards increased OPN, was not significantly different.
  • The results of this study indicate that OPN expression is present in normal salivary gland tissue, and is increased in certain salivary gland tumours, but further investigation is necessary to clarify its role.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Adenoid Cystic / metabolism. Neoplasm Proteins / metabolism. Osteopontin / metabolism. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


24. Ihrler S, Sendelhofert A, Weiler C, Hagedorn H, Harrison JD: Preinvasive intraductal neoplasia in salivary adenocarcinoma, not otherwise specified. Virchows Arch; 2006 Aug;449(2):159-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preinvasive intraductal neoplasia in salivary adenocarcinoma, not otherwise specified.
  • Preinvasive intraductal neoplasia of the salivary glands has only been identified in the rare salivary-duct carcinoma, whereas, it is an established feature of carcinomas of other glands.
  • A fortuitous observation of what appeared to be intraductal tumor in a salivary adenocarcinoma, not otherwise specified, led to the present investigation to determine whether intraductal neoplasia is a significant feature of this carcinoma.
  • Intraductal tumor is identified as the pre-invasive precursor of adenocarcinoma, not otherwise specified, and apparently develops in excretory ducts.
  • The findings support the possibility that different salivary tumors arise from different types of parenchymal cell.
  • Possibly intraductal neoplasia is a universal feature of many types of salivary tumor, but has been overlooked because of the need to use immunohistology to demonstrate it and because it may no longer be present as such when the tumor presents as a clinical lesion.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):75-84 [9426521.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):195-202 [9769121.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):356-61 [14762713.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] Am J Surg. 1982 Oct;144(4):423-31 [7125074.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):298-323 [11904344.001]
  • [Cites] Virchows Arch. 2002 May;440(5):519-26 [12021927.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(2):123-5 [8220820.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):958-67 [8780532.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Jan;101(1):102-4 [1728879.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):266-70 [15043319.001]
  • [Cites] Histopathology. 2002 Sep;41(3):244-9 [12207786.001]
  • (PMID = 16673121.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-14
  •  go-up   go-down


25. Seoane J, Varela-Centelles P, López-Niño J, Vázquez I, Abdulkader I, García-Caballero T: Gingival mucinous adenocarcinoma of a minor salivary gland. J Periodontol; 2010 Apr;81(4):626-31
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival mucinous adenocarcinoma of a minor salivary gland.
  • RESULTS: A definitive diagnosis of a mucinous adenocarcinoma (MAC), a very rare, high-grade malignancy tumor that more frequently appears in the elderly, was made.
  • With the definitive diagnosis of an MAC of the palate, the upper-left premolars were extracted using a box osteotomy, and the surgical wound was reconstructed with a Bichat fat-pad flap.
  • CONCLUSIONS: An MAC of a minor salivary gland may arise as a gingival exophytic lesion with a clinical appearance similar to a pyogenic granuloma.
  • The existence of a light speckled pattern on the surface of the lesion indicates that an incisional biopsy is needed before surgical treatment to make possible a definitive diagnosis.
  • To avoid delays in diagnosis and erroneous clinical approaches to exophytic gingival lesions, periodontists and practitioners should routinely perform a pathologic analysis to confirm the diagnosis when dealing with these kinds of lesions.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gingival Neoplasms / pathology. Palate, Hard / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367105.001).
  • [ISSN] 1943-3670
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Chandana SR, Conley BA: Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther; 2008 Apr;8(4):645-52
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland cancers: current treatments, molecular characteristics and new therapies.
  • Salivary gland cancers are relatively rare and quite diverse.
  • This article reviews the epidemiology, staging, molecular characteristics, and treatment evidence for the most common types of salivary cancers and suggests potential future diagnostic and treatment directions.
  • Progress in understanding the molecular and cell biology of salivary gland cancers may lead to the development of targeted therapies in these rare tumors.
  • Multidisciplinary and multi-institutional collaborative studies are needed to help improve survival in salivary gland cancers.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402531.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 81
  •  go-up   go-down


27. Matizonkas-Antonio LF, de Mesquita RA, de Souza SC, Nunes FD: TP53 mutations in salivary gland neoplasms. Braz Dent J; 2005;16(2):162-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations in salivary gland neoplasms.
  • Many studies have demonstrated that loss of TP53 gene function has an important role in the genesis of many neoplasms, including salivary gland neoplasms.
  • The purpose of this study was to examine the mutation profile of the TP53 gene in salivary gland neoplasms.
  • Genomic DNA was extracted from paraffin-embedded tissues of pleomorphic adenoma, carcinoma in pleomorphic adenoma, mucoepidermoid carcinoma, adenoid cystic carcinoma and polymorphous low grade adenocarcinoma.
  • The results of this study suggest that mutations in TP53 gene are related to salivary gland neoplasms pathogenesis and that exons 5 and 8 are most frequently involved.
  • [MeSH-major] Genes, p53 / genetics. Mutation / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma, Pleomorphic / genetics. Carcinoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / genetics. DNA, Neoplasm / genetics. Exons / genetics. Genome / genetics. Humans. Neoplasms, Multiple Primary / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475613.001).
  • [ISSN] 0103-6440
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


28. de Araújo VC, Furuse C, Cury PR, Altemani A, de Araújo NS: STAT3 expression in salivary gland tumours. Oral Oncol; 2008 May;44(5):439-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT3 expression in salivary gland tumours.
  • The aim of the present study was to evaluate the signal transducer and activator of transcription (STAT3) expression, which is constitutively active in different types of malignant tumours, in salivary gland tumours.
  • Fifty biopsies of salivary gland tumours (9 pleomorphic adenomas, 12 adenoid cystic carcinomas, 7 epithelial-myoepithelial carcinomas, 10 polymorphous low-grade adenocarcinomas and 12 mucoepidermoid carcinomas) and 10 normal salivary glands were immunohistochemically labeled for STAT3 and Phospho-STAT3 (STAT3P).
  • The results showed that, in normal salivary gland, STAT3 was expressed in cytoplasm and STAT3P in nuclei of all tissue cells, except in large mucous acinar cells for which both antibodies were negative.
  • In pleomorphic adenoma, the expression was the same as in normal glands.
  • The presence of STAT3 in the nuclei of malignant salivary gland tumours may represent an important event in oncogenesis probably contributing to tumour cell proliferation while blocking apoptosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. STAT3 Transcription Factor / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Female. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826306.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


29. Cheuk W, Chan JK: Advances in salivary gland pathology. Histopathology; 2007 Jul;51(1):1-20
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in salivary gland pathology.
  • This review summarizes the new findings on salivary gland pathology under the following categories: immunohistochemistry; molecular genetics; newly recognized tumour types; known tumour entities with new findings; and progression of salivary gland tumours.
  • In the application of immunohistochemistry, CD117 can aid in highlighting the luminal cell component of various salivary gland tumours, whereas p63 or maspin can aid in highlighting the abluminal cell component.
  • A high Ki67 index remains the most useful marker to predict adverse outcome in salivary gland carcinoma.
  • Newly recognized entities include: sclerosing polycystic adenosis (with recent molecular evidence supporting its neoplastic nature), sclerosing mucoepidermoid carcinoma with eosinophilia, keratocystoma, adenoma with additional stromal component (lymphadenoma, lipoadenoma and adenofibroma), cribriform adenocarcinoma of the tongue and signet ring adenocarcinoma of minor salivary gland.
  • Known tumour entities with new findings include: salivary duct carcinoma (with newly recognized mucinous, micropapillary and sarcomatoid variants), intraductal carcinoma (with controversies in terminology), mucoepidermoid carcinoma (with newly proposed grading parameters and oncocytic variant), epithelial-myoepithelial carcinoma (with newly recognized morphological variants), small cell carcinoma (with most cases being related to Merkel cell carcinoma), extranodal marginal zone B-cell lymphoma (with specific chromosomal translocation) and chronic sclerosing sialadenitis (being a component of IgG4-related sclerosing disease).
  • Progression of salivary gland tumours can take the form of malignant transformation of a benign tumour, progression from low-grade to high-grade carcinoma, dedifferentiation, or stromal invasion of an in situ carcinoma.
  • [MeSH-major] Immunohistochemistry / trends. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539914.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 142
  •  go-up   go-down


30. Bień S, Kamiński B, Kopczyński J, Sygut J: [The synchroneous tumors of different histopathology in the parotid salivary gland]. Otolaryngol Pol; 2006;60(5):703-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The synchroneous tumors of different histopathology in the parotid salivary gland].
  • Ipsilateral salivary gland tumors of different histological types are very rare.
  • In 5 cases pleomorphic adenoma was one of synchronous tumor--in 2 cases with adenocarcinoma and in single cases with salivary duct carcinoma, adenolymphoma, and myoepithelioma.
  • Following the review of literature concerning the problem, two concepts has been critically discussed--the real synchronous occurrence of two different tumors, and transformation of benign tumor of salivary neoplasm to its malignant form.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263242.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 24
  •  go-up   go-down


31. Uro-Coste E: [2009 update in salivary gland tumoral pathology]. Ann Pathol; 2009 Sep;29(4):274-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [2009 update in salivary gland tumoral pathology].
  • Histologic grade is a significant predictor of outcome in salivary gland carcinomas.
  • (iii) the MIB-1 proliferative index is the most useful immunohistochemical marker for prognosis of all salivary gland carcinomas.
  • In recent years, specific chromosomal translocations have been reported in some salivary glands tumors.
  • The PLAG1 and HMGA2 gene translocations have so far been identified only in pleomorphic adenomas, and their detection may potentially aid in diagnosis.
  • Newly recognized entities are summarized with special interest on differential diagnosis pitfalls: oncocytic mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, sclerosing polycystic adenosis, lymphadenoma, lipoadenoma, newly recognized morphological variants of epithelial-myoepithelial carcinoma, cribriform adenocarcinoma of the tongue, signet ring adenocarcinoma of minor salivary gland.
  • Specific chromosomal translocations and latest knowledge of the molecular mechanisms responsible for salivary glands oncogenesis (Epidermal Growth Factor Receptor [EGFR], phosphorylated AKT, topoisomerase II alpha, p27, Stat 3, maspin) should pave the way toward future targeted therapies.
  • [MeSH-major] Salivary Gland Neoplasms / pathology


32. Reid V, Yu Z, Schuman T, Li S, Singh P, Fong Y, Wong RJ: Herpes oncolytic therapy of salivary gland carcinomas. Int J Cancer; 2008 Jan 1;122(1):202-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes oncolytic therapy of salivary gland carcinomas.
  • We explored the activity of an attenuated, replication-competent, oncolytic HSV (NV1023) for the treatment of human salivary gland carcinomas.
  • NV1023 was able to successfully enter into 4 mucoepidermoid carcinoma (H292, H3118, HTB-41, UT-MUC-1) and 2 adenocarcinoma (HSY, HSG) cell lines, as measured by lacZ assays after exposure to 5 viral particles per cell (MOI 5).
  • These data suggest that oncolytic herpes viruses have significant efficacy entering, replicating within, and lysing human salivary gland carcinomas.
  • These promising biologic agents should be further investigated as novel therapy for patients with salivary carcinomas failing conventional treatment.
  • [MeSH-major] Adenocarcinoma, Follicular / therapy. Carcinoma, Mucoepidermoid / therapy. Herpesviridae Infections / therapy. Oncolytic Virotherapy. Salivary Gland Neoplasms / therapy. Simplexvirus / physiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17764117.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of salivary gland tumors.
  • OBJECTIVE: The aim of this report is to describe 3 cases of salivary gland tumors with intracranial extension associated to an extracerebral mass lesion, and to discuss the frequence, pathology and treatment of these very rare localizations.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • CONCLUSIONS: The intracranial extension of salivary gland tumors is a very rare event.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Cavaliéri Gomes C, da Silveira e Oliveira C, Santos Pimenta LG, De Marco L, Santiago Gomez R: Immunolocalization of DNMT1 and DNMT3a in salivary gland neoplasms. Pathobiology; 2009 May;76(3):136-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalization of DNMT1 and DNMT3a in salivary gland neoplasms.
  • OBJECTIVE: Salivary gland neoplasms pathogenesis has not been well established.
  • While DNMT3a is mostly involved in de novo methylation, DNMT1 acts as a maintenance methyltransferase.
  • We aimed to investigate the immunoexpression of DNMT3a and DNMT1 in minor salivary gland neoplasms, comparing it with normal tissue.
  • MATERIAL: Forty-four formalin-fixed and paraffin-embedded samples of pleomorphic adenoma, adenoid cystic carcinoma, mucoepidermoid carcinoma and polymorphous low-grade adenocarcinoma were included in the study.
  • CONCLUSION: Our results were not able to demonstrate a clear correlation between DNMT1 and DNMT3a immunoexpression and salivary gland neoplasms development.
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / biosynthesis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. DNA Methylation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Salivary Glands, Minor / metabolism. Salivary Glands, Minor / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19468253.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3A
  •  go-up   go-down


35. Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A: Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg; 2009 Jul;135(7):687-92
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma.
  • OBJECTIVE: To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas.
  • PATIENTS: A total of 24 patients, 12 with major salivary gland carcinoma who were treated with postoperative concurrent chemoradiotherapy from 1998 to 2007 (chemoradiation group), and a control group of 12 patients treated with postoperative radiation alone.
  • CONCLUSIONS: Locally advanced or high-grade salivary gland carcinomas follow an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma / surgery. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620591.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Tarakji B, Nassani MZ: Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types). Med Oral Patol Oral Cir Bucal; 2010 Sep;15(5):e697-703
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types).
  • OBJECTIVE: Our study aimed to characterize alteration in the immunohistochemical expression of p21 in normal tissue of the salivary gland surrounding pleomorphic adenoma, the tumor cells of pleomorphic adenomas, and carcinoma arising in pleomorphic adenoma.
  • STUDY DESIGN: A selected series of 29 cases of pleomorphic adenomas, and 27 cases of carcinoma ex-pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined.
  • RESULTS: The results showed that p21 expression was negative in the most components of normal tissue of the salivary gland surrounding pleomorphic adenoma, 24 cases out of 29 of the non tumour duct cells (82.8%), and 28 (96.6%) cases out of 29 of the acinar cells shows negative p21 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20383106.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


37. Prasad ML, Barbacioru CC, Rawal YB, Husein O, Wen P: Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol; 2008 Feb;21(2):105-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • Distinguishing adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma of the salivary glands is important for their management.
  • We studied the expression of several myoepithelial and basal/stem cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, metallothionein, maspin, and p63) by immunohistochemistry in 23 adenoid cystic carcinoma and 24 polymorphous low-grade adenocarcinoma, to identify the most useful marker or combination of markers that may help their diagnoses.
  • We noted diffuse expression of smooth muscle actin in 20 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), calponin in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), smooth muscle myosin heavy chain in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P=0.001), metallothionein in 22 adenoid cystic carcinoma vs eight polymorphous low-grade adenocarcinoma (P<0.001), maspin in 22 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma, and p63 in 21 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma.
  • In differentiating adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma, smooth muscle actin as a single ancillary test in support of the histological findings, appears to be as efficient as multiple immunohistochemical tests.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Epithelial Cells / metabolism. Myocytes, Smooth Muscle / metabolism. Neoplasm Proteins / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Salivary Glands, Minor / metabolism. Salivary Glands, Minor / pathology. Treatment Outcome


38. Aydin S, Ozercan IH, Dagli F, Aydin S, Dogru O, Celebi S, Akin O, Guzel SP: Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland. Biotech Histochem; 2005 May-Aug;80(3-4):163-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland.
  • Ghrelin (G-HH) synthesized in several tissues including salivary and stomach glands stimulates appetite in humans by modulating neuropeptide Y neurons in the hypothalamic arcuate nucleus.
  • We conducted a study using immunohistochemistry to determine whether salivary glands and stomach cancer tissues produce ghrelin.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Mucoepidermoid / metabolism. Peptide Hormones / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298902.001).
  • [ISSN] 1052-0295
  • [Journal-full-title] Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • [ISO-abbreviation] Biotech Histochem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ghrelin; 0 / Peptide Hormones
  •  go-up   go-down


39. Seethala RR: An update on grading of salivary gland carcinomas. Head Neck Pathol; 2009 Mar;3(1):69-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on grading of salivary gland carcinomas.
  • Histologic grade is a significant predictor of outcome in salivary gland carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Nov;133(5):702-8 [16274796.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2082-9 [18720358.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):409-16 [18971778.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Acta Otolaryngol. 2002 Oct;122(7):758-64 [12484654.001]
  • [Cites] Cancer. 1978 Jul;42(1):265-82 [208752.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Oct;99(10 Pt 1):835-8 [2221741.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):172-9 [1985714.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] Hum Pathol. 1997 May;28(5):595-600 [9158708.001]
  • [Cites] APMIS. 1997 Jul;105(7):559-65 [9269302.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1217-24 [9529011.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52 [10037280.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Br J Surg. 1958 Mar 18;45(193):477-87 [13536351.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jul;63(7):917-28 [16003616.001]
  • [Cites] Laryngoscope. 2008 Feb;118(2):258-62 [18030166.001]
  • (PMID = 20596994.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2807532
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Carcinoma ex pleomorphic adenoma / Grading / High grade transformation / Mucoepidermoid carcinoma / Salivary carcinoma
  •  go-up   go-down


40. Uchida K, Oga A, Mano T, Nagatsuka H, Ueyama Y, Sasaki K: Screening for DNA copy number aberrations in mucinous adenocarcinoma arising from the minor salivary gland: two case reports. Cancer Genet Cytogenet; 2010 Dec;203(2):324-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for DNA copy number aberrations in mucinous adenocarcinoma arising from the minor salivary gland: two case reports.
  • Mucinous adenocarcinoma (MAC) is a rare malignancy in the minor salivary gland.
  • To identify DNA copy number aberrations, we applied comparative genomic hybridization (CGH) to four samples of MAC in minor salivary gland derived from two patients: a primary tumor and two cervical metastatic lymph nodes from one patient, and a primary tumor from the other patient.
  • The DNA copy number aberrations detected in MAC in minor salivary glands were different from those reported for colorectal MAC.
  • The present findings are novel in identifying genomic alterations of MAC arising from the minor salivary gland.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Dosage. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21156253.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


41. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Grunstein E, Kacker A: Salivary gland cystadenocarcinoma of the mobile tongue, low-grade papillary adenocarcinoma variant: a case report. Ear Nose Throat J; 2006 Dec;85(12):829-30
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland cystadenocarcinoma of the mobile tongue, low-grade papillary adenocarcinoma variant: a case report.
  • Cystadenocarcinoma is a rare malignant neoplasm of the salivary gland.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Salivary Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Papillary cystadenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240709.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours.
  • OBJECTIVES: To investigate the topography of E-cadherin and its possible correlation with the histological phenotype of salivary gland tumours.
  • MATERIAL AND METHODS: Archival formalin-fixed, paraffin-embedded sections of 54 benign and 56 malignant tumours and 24 samples of normal and inflamed salivary gland tissue were studied immunohistochemically using an Envision/horseraddish peroxidase (HRP) technique.
  • RESULTS: In normal and inflamed salivary gland samples, E-cadherin was expressed at the membrane of acinar, myoepithelial and ductal cells located at cell-cell contact points.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • CONCLUSION: This study suggests a direct association of E-cadherin expression with neoplastic histologic phenotype, which is lost in the more undifferentiated and invasive epithelial salivary gland tumours.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenolymphoma / chemistry. Adenoma / chemistry. Adenoma, Pleomorphic / chemistry. Humans. Immunohistochemistry / methods. Salivary Gland Diseases / metabolism. Salivary Glands / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


44. Yih WY, Kratochvil FJ, Stewart JC: Intraoral minor salivary gland neoplasms: review of 213 cases. J Oral Maxillofac Surg; 2005 Jun;63(6):805-10
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoral minor salivary gland neoplasms: review of 213 cases.
  • PURPOSE: Minor salivary gland tumors (MSGTs) constitute a heterogeneous group of neoplasms with great histomorphologic variation.
  • This study reviews a large series of benign and malignant salivary gland tumors of the oral region and determines the incidence and the correlation of the histopathologic features with the clinical characteristics.
  • Of the 94 malignant MSGTs, mucoepidermoid carcinoma (MEC) (45 of 94), adenoid cystic carcinoma (22 of 94), and polymorphous low-grade adenocarcinoma (18 of 94) were the most common.
  • The palate is the most common site for minor gland neoplasms.
  • Benign labial salivary gland neoplasms are more common in the upper lip, and malignant labial tumors are more common in the lower lip.
  • [MeSH-major] Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944978.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Prabhu S, Kaveri H, Rekha K: Benign, malignant salivary gland tumors: comparison of immunohistochemical expression of e-cadherin. Oral Oncol; 2009 Jul;45(7):594-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign, malignant salivary gland tumors: comparison of immunohistochemical expression of e-cadherin.
  • The aim of the present study was to assess any variation in the immunohistochemical expression of E-cadherin in benign and malignant salivary gland tumors.
  • A total of 60 cases of benign and malignant salivary gland tumors were evaluated immunohistochemically for E-cadherin expression.
  • These included 10 cases of pleomorphic adenoma (PA), 2 cases of canalicular adenoma (CA), 2 cases of myoepithelioma (MY), 24 cases of adenoid cystic carcinoma (ACC), 12 cases of mucoepidermoid carcinoma (MEC), 9 cases of adenocarcinoma (AC) and 1 case of carcinoma ex pleomorphic adenoma (Ca Ex PA).
  • Statistically significant reduction in reactivity was evident in mucoepidermoid carcinoma and adenocarcinoma, when compared to pleomorphic adenoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cadherins / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Case-Control Studies. Humans. Myoepithelioma / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955011.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


46. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.
  • AIMS: To evaluate cytokeratin (CK) 7/20 expression patterns in salivary gland neoplasia.
  • METHODS AND RESULTS: Formalin-fixed paraffin embedded tissue from 153 salivary gland tumours were evaluated for CK7/20 immunoreactivity.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • All salivary gland neoplasms showed a CK7+/CK20- immunoprofile ranging from 5 to 100%.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-major] Gene Expression Profiling. Keratin-20 / metabolism. Keratin-7 / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


47. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • In the present study we analysed the expression of this molecule in salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • Furthermore its expression in serous acinar cells in sialadenitis and intercalated ductal cells in normal and inflammatory lesions may indicate a possible participation in pathogenesis of both neoplastic and non-neoplastic salivary gland diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


48. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers; 2006 Apr-Jun;21(2):106-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 13 expression in salivary gland tumors.
  • Petraki et al have previously described presence of hK13 in salivary gland tissue, localized to duct epithelia and some acinar cells.
  • The aim of this study was to determine whether hK13 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas (ACC), polymorphous low grade adenocarcinomas (PLGA), acinic cell carcinomas (ACI), mucoepidermoid carcinomas (MEC) and adenocarcinomas not otherwise specified (ANOS) of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors show high levels of expression of hK13.
  • Overall, staining in PA was significantly less than that seen in normal salivary gland tissue.
  • PLGA, ACC and ANOS each stained significantly more than normal salivary gland tissue while MEC and ACI did not.
  • In conclusion, we demonstrate the high expression of hK13 in several common salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Kallikreins / biosynthesis. Mouth Mucosa / metabolism. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Humans. Immunohistochemistry. Prognosis. Salivary Glands / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847813.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK13 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


49. Brandizzi D, Carino S, Cabrini RL: Ploidy studies of pleomorphic adenomas and minor salivary gland carcinomas of the palate. Acta Odontol Latinoam; 2008;21(1):105-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ploidy studies of pleomorphic adenomas and minor salivary gland carcinomas of the palate.
  • The aim of the present study was to evaluate the DNA content of palate aggressive pleomorphic adenomas (PA) and adenocarcinomas of the salivary glands.
  • Twelve cases of salivary gland tumors of the palate were selected from the archives of the Oral Pathology Department, Faculty of Dentistry, University of Buenos Aires (1966-2001).
  • Six cases corresponded to aggressive pleomorphic adenomas (PA) and the remaining six to adenocarcinomas (AD).
  • DNA content and the detection of aneuploidy would be prognostic aids in palate salivary gland carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Pleomorphic / genetics. Neoplasm Invasiveness / genetics. Palate, Hard / pathology. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Aneuploidy. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Humans. Mucous Membrane / pathology. Retrospective Studies. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841754.001).
  • [ISSN] 0326-4815
  • [Journal-full-title] Acta odontológica latinoamericana : AOL
  • [ISO-abbreviation] Acta Odontol Latinoam
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


50. Simpson RH, Desai S, Di Palma S: Salivary duct carcinoma in situ of the parotid gland. Histopathology; 2008 Oct;53(4):416-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary duct carcinoma in situ of the parotid gland.
  • AIMS: To describe three cases of purely in situ salivary duct carcinoma, so as better to define the entity.
  • METHODS AND RESULTS: Three primary tumours of the parotid gland are presented, in each case composed of cysts and ducts and lined by high nuclear grade epithelial cells.
  • The tumour cells expressed immunohistochemical markers seen in invasive salivary duct carcinoma of usual (high-grade) type.
  • CONCLUSIONS: Salivary duct carcinoma in situ is morphologically similar to breast ductal carcinoma in situ and, although our cases are few, salivary duct carcinoma in situ can possibly be subdivided into luminal and non-luminal cell types, as can analogous mammary neoplasms.
  • The present study cannot determine whether low-grade cribriform cystadenocarcinoma, architecturally similar but immunohistochemically different, is part of the spectrum of salivary duct carcinoma in situ, or whether it represents a separate entity.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Parotid Gland / pathology. Parotid Neoplasms / metabolism. Parotid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Salivary Ducts / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983607.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


51. Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol; 2006 Jun 10;24(17):2673-8
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy in the palliative management of advanced salivary gland cancers.
  • Cancers of the salivary glands are unusual lesions that vary widely in their histologic appearance and molecular characteristics.
  • The majority of patients for whom systemic therapy is considered will have either adenoid cystic carcinoma, mucoepidermoid carcinoma, or high-grade adenocarcinoma.
  • This article will review the available literature regarding the use of palliative chemotherapy for patients with advanced salivary gland cancer of these histologies, with an emphasis on the potential role of targeted agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Mucoepidermoid / drug therapy. Neoplasm Recurrence, Local / drug therapy. Palliative Care. Salivary Ducts. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Quinazolines; 0 / Receptors, Androgen; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Number-of-references] 87
  •  go-up   go-down


52. Mücke T, Kesting MR, Hohlweg-Majert B, Hölzle F, Wolff KD: The role of bronchoscopy and gastroscopy in intraoral minor salivary gland carcinomas at initial staging. Br J Oral Maxillofac Surg; 2009 Dec;47(8):608-11
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bronchoscopy and gastroscopy in intraoral minor salivary gland carcinomas at initial staging.
  • Intraoral minor salivary gland carcinomas are rare tumours the incidence, distribution, and prognostic factors of which differ.
  • The aim of this study was to assess the value of bronchoscopy and gastroscopy in the routine staging of minor salivary gland cancers.
  • We retrospectively reviewed the casenotes of 95 patients who had presented with newly diagnosed intraoral minor salivary gland carcinomas.
  • Data were collected about abnormalities detected during endoscopic screening; a biopsy was taken if reasonable and if the resulting diagnosis influenced the planned treatment.
  • For therapeutic, diagnostic, and prognostic reasons bronchoscopy and gastroscopy should be included routinely into staging of intraoral minor salivary gland carcinomas.
  • [MeSH-major] Bronchoscopy. Carcinoma / pathology. Gastroscopy. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy. Bronchitis / diagnosis. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Esophageal Neoplasms / diagnosis. Female. Gastroenteritis / diagnosis. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Male. Mass Screening. Middle Aged. Mouth Mucosa / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / diagnosis. Palate / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162382.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


53. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • RESULTS: Basal cell adenocarcinomas are slow-growing tumours that most commonly involve the parotid gland and very rarely involve minor salivary glands.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


54. Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T, Hatayama Y, Nagahata M, Yokoyama J, Shinkawa H: Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol; 2006 Oct;11(5):403-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.
  • Malignant neoplasms of the salivary gland are uncommon entities in which surgical resection of the primary lesion has been accepted as a standard therapeutic option.
  • We treated one patient with recurrent adenoid cystic carcinoma arising from the sublingual gland and one patient with primary adenocarcinoma arising from the parotid gland with transfemoral intraarterial chemotherapy, based on full-dose cisplatin and docetaxel and concurrent external-beam radiotherapy.
  • The concomitant chemoradiotherapy of cisplatin and docetaxel seemed to be a practicable option for patients with recurrent and unresectable salivary gland carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Parotid Neoplasms / drug therapy. Parotid Neoplasms / radiotherapy. Sublingual Gland Neoplasms / drug therapy. Sublingual Gland Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / radiotherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 22;355(9200):281-3 [10675076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1874-7 [1913539.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Arch Otolaryngol. 1982 Apr;108(4):221-4 [6280657.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):82-92 [3623942.001]
  • [Cites] Head Neck. 2002 Apr;24(4):406-10 [11933184.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4135-40 [15736464.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):541-7 [11169936.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3781-3 [11268454.001]
  • [Cites] Head Neck. 2005 Jan;27(1):65-71 [15459915.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1842-50 [8620502.001]
  • (PMID = 17058139.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Cavalcante RB, Lopes FF, Ferreira AS, Freitas Rde A, de Souza LB: Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors. Braz Dent J; 2007;18(3):192-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors.
  • In order to evaluate the immunohistochemical markers expressed by these cells, a panel of antibodies composed of vimentin, calponin and HHF-35 was applied to 28 salivary gland tumors.
  • In conclusion, the combination of calponin and vimentin is suggested for the identification of myoepithelial cells in salivary gland tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Muscle Proteins / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176708.001).
  • [ISSN] 1806-4760
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Vimentin; 0 / calponin
  •  go-up   go-down


56. Vargas PA, Torres-Rendon A, Speight PM: DNA ploidy analysis in salivary gland tumours by image cytometry. J Oral Pathol Med; 2007 Jul;36(6):371-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA ploidy analysis in salivary gland tumours by image cytometry.
  • AIM: To determine whether DNA ploidy by image cytometry is a good diagnostic tool to distinguish benign and malignant salivary gland tumours.
  • METHODS: A total of 62 salivary gland tumours were studied.
  • According to the World Health Organization (WHO) classification, there were 14 mucoepidermoid carcinomas (MEC), 11 adenoid cystic carcinomas (ACC), 10 pleomorphic adenomas (PA), 10 carcinoma ex PA (CEPA), 9 acinic cell carcinomas (ACCa), 3 polymorphous low-grade adenocarcinomas (PLGA), 2 papillary cystadenocarcinomas (PC), 1 myoepithelial carcinoma (MC), 1 undifferentiated carcinoma (UC) and 1 mucinous adenocarcinoma (MA).
  • RESULTS: Fifty-three of 62 salivary gland tumours were uniformly diploid.
  • CONCLUSIONS: The vast majority of salivary gland tumours were diploid.
  • [MeSH-major] DNA, Neoplasm / analysis. Image Cytometry. Ploidies. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559500.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


57. Furuse C, Cury PR, Altemani A, dos Santos Pinto D Jr, de Araújo NS, de Araújo VC: Beta-catenin and E-cadherin expression in salivary gland tumors. Int J Surg Pathol; 2006 Jul;14(3):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin and E-cadherin expression in salivary gland tumors.
  • This study evaluated the expression of E-cadherin and beta-catenin in salivary gland tumors.
  • Healthy salivary glands were used as controls.
  • Epithelial-myoepithelial carcinomas present changes in [.beta]-catenin expression but the other salivary tumors studied do not, which may reflect divergence in tumorigenesis of this extensive subset of salivary gland tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cadherins / metabolism. Carcinoma, Adenoid Cystic / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Surg Pathol. 2007 Apr;15(2):219-20 [17478787.001]
  • (PMID = 16959701.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


58. Dhanuthai K, Boonadulyarat M, Jaengjongdee T, Jiruedee K: A clinico-pathologic study of 311 intra-oral salivary gland tumors in Thais. J Oral Pathol Med; 2009 Jul;38(6):495-500
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinico-pathologic study of 311 intra-oral salivary gland tumors in Thais.
  • BACKGROUND: There have been several epidemiologic studies on intra-oral salivary gland tumors in several countries, but little is known of these tumors in Thailand.
  • OBJECTIVES: To determine the relative frequency and distribution of various types of intra-oral salivary gland tumors in the Thai population.
  • METHODS: The files of the Department of Oral Pathology, Faculty of Dentistry, Chulalongkorn University, from 1969 to 2007 were searched for intra-oral salivary gland tumors.
  • RESULTS: Of the 16,358 accessioned cases, 311 cases (1.90%) were diagnosed as intra-oral salivary gland tumors.
  • Pleomorphic adenoma was the most common intra-oral salivary gland tumor.
  • CONCLUSIONS: Pleomorphic adenoma is the most common intra-oral salivary gland tumor and the most common benign intra-oral salivary gland tumor, while mucoepidermoid carcinoma is the most common malignant intra-oral salivary gland tumor.
  • Intra-oral salivary gland tumors in Thailand elicit similar trend as in previous studies, with only minor differences such as the ranking of some tumors, the higher incidence of intra-bony location, and the lower incidence of polymorphous low-grade adenocarcinoma.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Child. Female. Humans. Incidence. Male. Middle Aged. Palatal Neoplasms / epidemiology. Retrospective Studies. Sex Factors. Thailand / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594840.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


59. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L: Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol; 2009 Nov;45(11):986-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
  • Salivary gland carcinomas (SGCs) are rare tumors encompassing a wide spectrum of histologic/biologic entities.
  • EGFR was the most expressed TKRs (71%) and it was found across all histotypes. c-Kit expression was mainly restricted to adenoid cystic carcinoma (78%) while HER2 expression, mostly sustained by gene amplification, correlated with salivary duct carcinoma (SDC) in 44% of cases and adenocarcinoma, not otherwise specified (AD, NOS) in 21% of cases.
  • AR was found in 13% of samples, restricted to SDC and AD, NOS and it was co-expressed with HER2 in more than half of the SDC cases.
  • [MeSH-major] Carcinoma / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptors, Steroid / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Retrospective Studies


60. Iyer NG, Kim L, Nixon IJ, Palmer F, Kraus D, Shaha AR, Shah JP, Patel SG, Ganly I: Factors predicting outcome in malignant minor salivary gland tumors of the oropharynx. Arch Otolaryngol Head Neck Surg; 2010 Dec;136(12):1240-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting outcome in malignant minor salivary gland tumors of the oropharynx.
  • OBJECTIVES: to report our experience in the care of patients with minor salivary gland cancers occurring only in the oropharynx and to determine factors predictive of outcome.
  • PATIENTS: sixty-seven patients with malignant minor salivary gland tumors were identified from a preexisting database of patients with cancers of the oropharynx between January 1985 and December 2005.
  • RESULTS: the most common histologic types were mucoepidermoid carcinoma in 26 patients (39%), adenoid cystic carcinoma in 16 (24%), adenocarcinoma in 16 (24%), and malignant mixed tumor in 7 (10%).
  • CONCLUSION: clinical T stage, anatomic subsite, and margin status are independent predictors of outcome of patients with minor salivary gland cancers of the oropharynx.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasm Recurrence, Local / epidemiology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Salivary Glands, Minor. Survival Rate / trends. Time Factors. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173374.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Mäkitie AA, Pintor Dos Reis P, Arora S, Macmillan C, Warner GC, Sukhai M, Dardick I, Perez-Ordonez B, Wells R, Brown D, Gilbert R, Freeman J, Gullane P, Irish J, Kamel-Reid S: Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. Lab Invest; 2005 Aug;85(8):947-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model.
  • The molecular mechanisms underlying salivary gland tumorigenesis remain unclear.
  • In order to identify genetic changes that occur during the development of invasive adenocarcinoma from normal salivary gland, we used the Smgb-Tag transgenic mouse model.
  • This transgene induces the progressive development of dysplasia to invasive adenocarcinoma in the submandibular salivary gland.
  • Gene expression patterns from 20 submandibular glands (two normal, nine dysplasia and nine adenocarcinoma samples) were assessed using a mouse 15 K cDNA array.
  • Further analysis identified 25 significantly overexpressed and 28 underexpressed cDNA sequences in adenocarcinoma as compared to dysplasia.
  • Differential expression of five genes (Lcn2, Ptn, Cd24a, Mapk6 and Rnps1) was validated by quantitative real-time RT-PCR in a total of 48 mouse salivary gland tissues (seven histologically normal, 13 dysplasias and 28 adenocarcinomas), including the 20 samples analyzed by cDNA arrays.
  • Immunohistochemical analysis was used to validate the expression of Ptn and Cd24a at the protein level in a subset of 16 mouse salivary glands (four normal, five dysplasia and seven adenocarcinoma samples), as well as in 23 human submandibular gland tumors (16 pleomorphic adenomas, three adenoid cystic carcinomas, one acinic cell carcinoma, one adenocarcinoma NOS, one myoepithelial and one mucoepidermoid carcinoma).
  • We thus demonstrated that the Smgb-Tag transgenic mouse model is a useful tool for the identification of genes that are deregulated in salivary gland adenocarcinomas.
  • Our data suggest that Ptn and Cd24a may be genetic markers associated with salivary gland tumorigenesis and/or progression.
  • [MeSH-major] Adenocarcinoma / genetics. Disease Models, Animal. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880136.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


63. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 8 expression in salivary gland tumors.
  • The human kallikrein 8 protein (KLK8) is expressed in many normal tissues including esophagus, skin, testis, tonsil, kidney, breast, and salivary gland, and is found in biological fluids including breast milk, amniotic fluid, seminal fluid and serum.
  • The aim of this study was to determine whether KLK8 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors show high levels of expression of KLK8.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Kallikreins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands, Minor / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


64. Li LJ, Li Y, Wen YM, Liu H, Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol; 2008 Feb;44(2):187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of salivary gland tumor cases in West China in past 50 years.
  • In our study, 3461 cases of salivary gland tumor treated between 1955 and 2002 at West China Stomatology Hospital of Sichuan University were retrospectively analyzed, and compared with the previous reports.
  • The findings are as follows: the average ages of salivary gland tumor patients were 41.38 years for the benign cases and 45.20 for the malignant ones; the male:female ratio was 0.
  • 99:1 in the benign cases and 1.34:1 in the malignant ones; primary tumors were mostly in the parotid gland, palate and submandibular gland in sequence.
  • Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor and basal cell adenoma, whereas mucoepidermoid carcinoma, adenoid cystic carcinoma and adenocarcinoma not otherwise specified were the most frequent malignant tumors.
  • The incidence of salivary gland tumors increased with age.
  • The parotid gland and palate were the most common locations of salivary gland tumors.
  • [MeSH-major] Adenoma, Pleomorphic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Salivary Gland Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Incidence. Infant. Male. Middle Aged. Palatal Neoplasms / pathology. Parotid Neoplasms / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oral Oncol. 2011 Sep;47(9):929-30
  • (PMID = 17418612.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Moore BA, Burkey BB, Netterville JL, Butcher RB 2nd, Amedee RG: Surgical management of minor salivary gland neoplasms of the palate. Ochsner J; 2008;8(4):172-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of minor salivary gland neoplasms of the palate.
  • OBJECTIVE: Minor salivary gland tumors are uncommon, accounting for up to 15% of salivary gland neoplasms.
  • We describe our experience with both benign and malignant tumors of the palatal minor salivary glands, focusing on the extent of resection and options for defect reconstruction.
  • RESULTS: From 1994 to 2002, 37 patients with primary neoplasms originating in the palatal minor salivary glands were treated at a single institution.
  • The most common malignant tumor encountered was low grade polymorphous adenocarcinoma, followed by mucoepidermoid carcinoma, and adenoid cystic carcinoma.
  • CONCLUSIONS: Neoplasms of the minor salivary glands in the palate may be excised, with limits dictated by tumor histopathology and perineural invasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dentomaxillofac Radiol. 1997 Jan;26(1):16-21 [9446985.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Jun;121(6):607-12 [7772309.001]
  • [Cites] Head Neck. 1998 Dec;20(8):699-706 [9790291.001]
  • [Cites] Arch Otolaryngol. 1978 Sep;104(9):501-4 [210749.001]
  • [Cites] Ear Nose Throat J. 1989 Feb;68(2):137-40 [2656236.001]
  • [Cites] Am J Otolaryngol. 1989 Jul-Aug;10(4):250-6 [2764237.001]
  • [Cites] Laryngoscope. 1987 Nov;97(11):1343-5 [2823035.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33 [2845326.001]
  • [Cites] Laryngoscope. 1980 Apr;90(4):576-84 [6767146.001]
  • [Cites] Laryngoscope. 1995 Nov;105(11):1155-60 [7475867.001]
  • [Cites] J Oral Maxillofac Surg. 1994 May;52(5):454-9 [8169706.001]
  • [Cites] J Laryngol Otol. 1993 Sep;107(9):858-61 [8228611.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Mar;108(3):304-5 [8385307.001]
  • [Cites] J Okla Dent Assoc. 1996 Spring;86(4):50-2 [9540689.001]
  • [Cites] Histopathology. 1998 Jun;32(6):521-9 [9675591.001]
  • [Cites] Otolaryngol Clin North Am. 1999 Oct;32(5):875-86 [10477793.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):548-52 [10547468.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1319-28 [11023093.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):837-41 [11448360.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):946-51 [12782803.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):935-42 [6692293.001]
  • [Cites] Acta Cytol. 1998 Jul-Aug;42(4):888-98 [9684573.001]
  • (PMID = 21603498.001).
  • [ISSN] 1524-5012
  • [Journal-full-title] The Ochsner journal
  • [ISO-abbreviation] Ochsner J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3096363
  • [Keywords] NOTNLM ; Palate / salivary gland neoplasms
  •  go-up   go-down


66. Kakarala K, Bhattacharyya N: Survival in oral cavity minor salivary gland carcinoma. Otolaryngol Head Neck Surg; 2010 Jul;143(1):122-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in oral cavity minor salivary gland carcinoma.
  • OBJECTIVE: To describe the epidemiology and comparative survival for minor salivary gland cancer of the oral cavity.
  • SUBJECTS AND METHODS: Cases of minor salivary gland cancer of the oral cavity were extracted from the Surveillance, Epidemiology, and End Results database (1988-2005) and staged.
  • RESULTS: A total of 639 salivary gland cancers of the oral cavity (55% female; mean age, 56 years) were identified with complete staging information, consisting of 318 mucoepidermoid, 169 adenoid cystic, 139 adenocarcinoma, and 14 acinic cell cancers.
  • Overall mean survival (months) was 157.9 and was similar across histologic subtypes: mucoepidermoid (172.4), adenoid cystic (141.4), acinic cell (138.7), and adenocarcinoma (147.2).
  • CONCLUSION: T stage and N stage are the most powerful predictors of survival in minor salivary gland carcinoma of the oral cavity.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20620630.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ishida M, Hotta M, Kushima R, Tsuruoka S, Ohji M, Okabe H: Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland. Rinsho Byori; 2009 Aug;57(8):746-51
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • Ductal adenocarcinoma of the lacrimal gland is extremely rare; to our knowledge, only seven de novo cases and one case of ductal adenocarcinoma ex pleomorphic adenoma have been reported in the literature.
  • Here, we report a case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • A 70-year-old Japanese female received the resection of the recurrent lacrimal gland tumor (second surgery), under the clinical diagnosis of recurrent pleomorphic adenoma, fifteen years after the initial surgical resection.
  • The resected tumor was composed of recurrent pleomorphic adenoma and adenocarcinoma.
  • Adenocarcinoma component showed infiltrative papillo-tubular or microcystic growth of carcinoma cells, which had pleomorphic large nuclei with prominent nucleoli and rich eosinophilic cytoplasm.
  • Accordingly, the diagnosis of ductal adenocarcinoma ex pleomorphic adenoma was made.
  • These data suggests that lacrimal ductal adenocarcinoma appears to have a poor prognosis, similar to salivary duct carcinoma, which is one of the most aggressive salivary carcinoma.
  • And further study is needed to clarify the clinicopathological features of the lacrimal ductal adenocarcinoma.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Eye Neoplasms / diagnosis. Eye Neoplasms / pathology. Lacrimal Apparatus. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764409.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


68. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant minor salivary gland tumors of the larynx].
  • OBJECTIVE: To study the clinical features, treatment and prognosis of malignant minor salivary gland tumors of the larynx.
  • METHODS: Treatment and outcome were retrospectively analyzed in a consecutive series of 15 patients with malignant minor salivary gland tumors of the larynx treated in this hospital from 1959 to 2005.
  • Ten patients (66.7%) had adenoid cystic carcinoma and 2 (13.3%) had adenocarcinoma.
  • The other three patients had mucoepidermoid carcinomas, polymorphic adenocarcinoma and base cell carcinoma respectively.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.
  • [MeSH-major] Laryngeal Neoplasms / therapy. Salivary Gland Neoplasms / therapy. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Ponniah I, SureshKumar P, Karunakaran K: Clear cell carcinoma of minor salivary gland--case report. Ann Acad Med Singapore; 2007 Oct;36(10):857-60
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of minor salivary gland--case report.
  • INTRODUCTION: Clear cell carcinoma is a rare low-grade carcinoma that almost exclusively occurs in the minor salivary glands.
  • This tumour is one of the new additions in the recent World Health Organization (WHO) classification of salivary gland tumours.
  • TREATMENT AND OUTCOME: A preoperative diagnosis of primary clear cell carcinoma of salivary gland with focal surface epithelial dysplasia was rendered after thorough clinical examination to rule out renal origin.
  • CONCLUSION: We report a case of clear cell carcinoma of intra-oral minor salivary gland and draw comparisons with metastatic clear cell carcinoma of renal origin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Salivary Glands, Minor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987239.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


70. Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Pession A: p63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation. Int J Surg Pathol; 2005 Oct;13(4):329-35
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation.
  • To illustrate the role of p63 and its truncated variants in salivary gland tumors, 23 consecutive tumors and 6 normal salivary glands were studied immunohistochemically with anti-p63 antibody and by reverse transcriptase (RT) and nested polymerase chain reaction (PCR) to detect p63 isoform expression.
  • Normal salivary glands: p63 antibody-stained basal and myoepithelial cells; by RT and nested PCR, the 2 main isoforms were present, whereas DeltaNp73L was absent.
  • Tumors: p63 antibody was positive in the following: Warthin tumor (WT) (3/3), oncocytoma (OC) (1/1), pleomorphic adenoma (PA) (7/7), polymorphous-low-grade adenocarcinoma (PLGA) (3/3), adenoid-cystic carcinoma (ADCC)(3/4), epithelial-myoepithelial-cell carcinoma (EMC) (1/1), and myoepithelial-cell carcinoma (MCC) (1/1).
  • The DeltaNp73L isoform was present in tumoral tissue but absent in normal salivary gland.
  • These data suggest that p63, particularly its splice variant DeltaNp73L, is involved in the neoplastic transformation of salivary glands.
  • [MeSH-major] Cell Transformation, Neoplastic. Phosphoproteins / genetics. Phosphoproteins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Trans-Activators / genetics. Trans-Activators / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adult. Aged. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cell Proliferation. DNA-Binding Proteins. Exons. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Myoepithelioma / metabolism. Myoepithelioma / pathology. Polymerase Chain Reaction. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction. Salivary Glands / cytology. Salivary Glands / metabolism. Salivary Glands / pathology. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273188.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


71. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB: Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer; 2005 Jun 15;103(12):2544-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy alone or combined with surgery for salivary gland carcinoma.
  • BACKGROUND: The authors analyzed the outcomes of patients treated with radiotherapy (RT) alone or combined with surgery for carcinoma of the salivary glands.
  • CONCLUSIONS: A substantial proportion of patients with salivary gland carcinoma were cured with surgery combined with adjuvant RT.
  • [MeSH-major] Salivary Gland Neoplasms / radiotherapy. Salivary Gland Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Mucoepidermoid / surgery. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880750.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Vargas PA, Speight PM, Bingle CD, Barrett AW, Bingle L: Expression of PLUNC family members in benign and malignant salivary gland tumours. Oral Dis; 2008 Oct;14(7):613-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PLUNC family members in benign and malignant salivary gland tumours.
  • OBJECTIVES: The aim of this study was to determine the expression of PLUNC proteins in benign and malignant salivary gland tumours and thus their potential use as diagnostic and / or prognostic tools.
  • MATERIALS AND METHODS: A tissue microarray was assembled from 64 salivary gland tumours including adenoid cystic carcinoma, carcinoma ex-pleomorphic adenoma, mucoepidermoid carcinoma, polymorphous low-grade adenocarcinoma, pleomorphic adenoma, acinic cell carcinoma, myoepithelial carcinoma and papillary cystadenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Mucoepidermoid / metabolism. Cystadenocarcinoma, Papillary / metabolism. Glycoproteins / biosynthesis. Phosphoproteins / biosynthesis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dent Res. 2005 Feb;84(2):149-53 [15668332.001]
  • [Cites] J Pathol. 2005 Mar;205(4):491-7 [15685591.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1469-78 [16739998.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] J Oral Pathol Med. 2006 Aug;35(7):392-401 [16827841.001]
  • [Cites] J Laryngol Otol. 2006 Dec;120(12):1077-80 [16995970.001]
  • [Cites] J Oral Pathol Med. 2007 Jul;36(6):371-6 [17559500.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2679-87 [1370829.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1109-15 [15048992.001]
  • [Cites] Genetics. 1980 May;95(1):129-41 [6159249.001]
  • [Cites] Protein Sci. 2004 Feb;13(2):422-30 [14739326.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1940-9 [14612907.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):237-42 [14573783.001]
  • [Cites] Biochem Soc Trans. 2003 Aug;31(Pt 4):777-80 [12887304.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):80-90 [12874788.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6 [12612759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1099-104 [12538848.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Hum Mol Genet. 2002 Apr 15;11(8):937-43 [11971875.001]
  • [Cites] Auris Nasus Larynx. 2002 Jan;29(1):87-90 [11772498.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 2;1493(3):363-7 [11018263.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1440-7 [8944036.001]
  • [Cites] Diagn Cytopathol. 1998 Oct;19(4):244-9 [9784985.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13698-703 [10224143.001]
  • [Cites] J Oral Pathol Med. 1993 Aug;22(7):327-30 [8229870.001]
  • (PMID = 18221458.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 076491; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Phosphoproteins
  • [Other-IDs] NLM/ PMC2853704; NLM/ UKMS29166
  •  go-up   go-down


73. Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG: Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jan;103(1):77-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases.
  • Basal cell adenocarcinoma (BCA) is an unusual salivary gland malignancy that very rarely affects the minor glands.
  • Here we present 2 cases of BCA arising in the minor salivary glands of the left cheek and junction of the hard and soft palate, respectively.
  • A comprehensive literature review revealed only 21 previously reported cases of BCA of oral minor salivary glands.
  • This is an exceptionally rare salivary gland tumor, which, despite its low-grade behavior, demands complete surgical removal with adequate margins.
  • Immunohistochemical studies may complement a thorough histopathologic analysis in discriminating BCA from other salivary gland tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178498.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


74. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer; 2008 Jul 8;99(1):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
  • Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib.
  • By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Pathol Int. 2007 May;57(5):233-44 [17493170.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • (PMID = 18542074.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2453031
  •  go-up   go-down


75. Ohshiro K, Rayala SK, Kondo S, Gaur A, Vadlamudi RK, El-Naggar AK, Kumar R: Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res; 2007 Sep 1;67(17):8164-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated the role of PELP1 in resveratrol-induced autophagy in lung cancer and salivary gland adenocarcinoma cell lines.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Cell Cycle / drug effects. Cell Proliferation / drug effects. Co-Repressor Proteins. Endosomal Sorting Complexes Required for Transport. Gene Expression Regulation, Neoplastic / drug effects. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Microtubule-Associated Proteins / metabolism. Models, Biological. Phosphoproteins / metabolism. Protein Transport / drug effects. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Transcription Factors. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804729.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA109379; United States / NCI NIH HHS / CA / CA65746
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Co-Repressor Proteins; 0 / Endosomal Sorting Complexes Required for Transport; 0 / Microtubule-Associated Proteins; 0 / PELP1 protein, human; 0 / Phosphoproteins; 0 / Receptors, Estrogen; 0 / Stilbenes; 0 / Trans-Activators; 0 / Transcription Factors; 0 / hepatocyte growth factor-regulated tyrosine kinase substrate; 0 / light chain 3, human; Q369O8926L / resveratrol
  •  go-up   go-down


76. Ito FA, Ito K, Coletta RD, Vargas PA, Lopes MA: Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. Braz Oral Res; 2009 Oct-Dec;23(4):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors.
  • The aim of this work was to study the immunohistochemical expression of androgen receptor, estrogen receptor and progesterone receptor in pleomorphic adenomas, Warthin's tumors, mucoepidermoid carcinomas and adenoid cystic carcinomas of salivary glands.
  • However, androgen receptors can play a role in a small set of salivary gland tumors, and this would deserve further studies.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Complex and Mixed / pathology. Receptors, Androgen / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027446.001).
  • [ISSN] 1807-3107
  • [Journal-full-title] Brazilian oral research
  • [ISO-abbreviation] Braz Oral Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


77. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R: Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia; 2006 Oct;8(10):879-84
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival.
  • PATIENTS AND METHODS: We analyzed heparanase expression in 60 patients (aged 59 +/- 17 years) with malignant salivary tumors (39 males and 21 females) using immunohistochemistry.
  • CONCLUSIONS: Heparanase expression levels inversely correlate with the survival rates of salivary gland cancer patients, clearly indicating that heparanase is a reliable prognostic factor for this malignancy and an attractive target for anticancer drug development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] Lab Invest. 2003 May;83(5):613-22 [12746471.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1167-75 [11021821.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M99-108 [11250066.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1299-305 [11350898.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4655-9 [11406531.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1661-3 [11427519.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):341-7 [11489924.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):295-301 [11494228.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1270-5 [11953884.001]
  • [Cites] Oncology. 2003;64(4):389-98 [12759537.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1505-10 [14504050.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8749-56 [14695190.001]
  • [Cites] J Pathol. 2004 May;203(1):594-602 [15095483.001]
  • [Cites] J Cell Sci. 2004 May 1;117(Pt 11):2249-58 [15126626.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23536-41 [15044433.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30 [15316057.001]
  • [Cites] J Surg Oncol. 2004 Sep 15;87(4):174-81 [15334632.001]
  • [Cites] Science. 1983 May 6;220(4597):611-3 [6220468.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2704-11 [6601984.001]
  • [Cites] J Biol Chem. 1984 Feb 25;259(4):2283-90 [6698965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(8):2292-6 [3470794.001]
  • [Cites] Am J Pathol. 1988 Feb;130(2):393-400 [3277442.001]
  • [Cites] Arteriosclerosis. 1989 Jan-Feb;9(1):21-32 [2463827.001]
  • [Cites] Biochemistry. 1989 Feb 21;28(4):1737-43 [2541764.001]
  • [Cites] Cell. 1997 Nov 14;91(4):439-42 [9390552.001]
  • [Cites] Nat Med. 1999 Jul;5(7):793-802 [10395325.001]
  • [Cites] Nat Med. 1999 Jul;5(7):803-9 [10395326.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):183-7 [10405343.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24153-60 [10446189.001]
  • [Cites] J Histochem Cytochem. 2005 Jan;53(1):3-11 [15637333.001]
  • [Cites] FASEB J. 2005 Feb;19(2):211-21 [15677344.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):593-8 [12065771.001]
  • [Cites] Surgery. 2002 Aug;132(2):326-33 [12219030.001]
  • [Cites] Angew Chem Int Ed Engl. 2002 Feb 1;41(3):391-412 [12491369.001]
  • [Cites] Trends Biochem Sci. 2000 Aug;25(8):349-51 [10916150.001]
  • (PMID = 17032504.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106456; United States / NCI NIH HHS / CA / R01-CA106456
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  • [Other-IDs] NLM/ PMC1715927
  •  go-up   go-down


78. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Another family of salivary gland-type mammary epithelial neoplasms is devoid of myoepithelial cells.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


79. Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H, Ishikawa A, Okada N: Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report. Pathol Res Pract; 2006;202(6):475-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report.
  • Basal cell adenocarcinomas (BCACs) of the oral minor salivary gland are very rare neoplasms.
  • We report on an 86-year-old woman with BCAC arising from the minor salivary gland in the soft palate.
  • [MeSH-major] Adenocarcinoma / pathology. Palate, Soft / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487667.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Bell D, Luna MA: Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm. Ann Diagn Pathol; 2009 Jun;13(3):201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm.
  • Carcinomas arising in or from the epithelial component of preexisting parotid Warthin tumors (WTs) are rare; the other histologic types of carcinoma found to arise from WTs are adenocarcinoma not otherwise specified, undifferentiated, mucoepidermoid, squamous cell, and oncocytic.
  • The aim of this study is to describe the clinicopathologic features of a distinct salivary gland neoplasm, previously undescribed, with a striated duct phenotype arising from WT.
  • We have designated this neoplasm "Warthin adenocarcinoma" (WA).
  • Anderson Cancer Center for cases of malignant WT and salivary adenocarcinoma not otherwise specified diagnosed from January 1, 1985, through December 31, 2006, and evaluated patients' medical records and pathologic material.
  • We identified 2 cases of WA; both patients were women, 44 and 60 years of age, with 4.0- and 4.5-cm tumors in the left parotid gland.
  • Warthin adenocarcinoma is a unique salivary gland carcinoma representing the malignant epithelial counterpart of WT.
  • [MeSH-major] Adenocarcinoma / pathology. Adenolymphoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433301.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Arathi N, Bage AM: Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):103-5
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence.
  • Polymorphous low-grade adenocarcinoma (PLGA) is a rare salivary gland malignant tumor of low aggressiveness, commonly occurring in minor salivary glands.
  • Its occurrence in major salivary gland has been documented albeit rarely.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):166-7 [20090256.001]
  • (PMID = 19136798.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


82. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK: Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys; 2006 Nov 15;66(4):1044-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas.
  • PURPOSE: To review a single-institution experience with the management of salivary gland cancers treated by radiation alone.
  • METHODS AND MATERIALS: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy).
  • Histology was: 14 mucoepidermoid (31%), 10 adenocarcinoma (22%), 8 adenoid cystic (18%), 4 undifferentiated (9%), 4 acinic (9%), 2 malignant mixed (4%), 2 squamous (4%), and 1 salivary duct carcinoma (2%).
  • CONCLUSION: Radiation therapy alone is a reasonable alternative to surgery in the definitive management of salivary gland cancers and results in long-term survival in a significant proportion of patients.
  • [MeSH-major] Carcinoma / radiotherapy. Salivary Gland Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965870.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Chen AM, Garcia J, Granchi PJ, Johnson J, Eisele DW: Late recurrence from salivary gland cancer: when does "cure" mean cure? Cancer; 2008 Jan 15;112(2):340-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence from salivary gland cancer: when does "cure" mean cure?
  • BACKGROUND: The purpose of the current study was to determine the incidence of late recurrences, which were defined as those occurring >or=5 years after initial therapy, among patients treated for salivary gland cancer.
  • METHODS: Between 1960 and 2000, 145 patients underwent definitive therapy for localized carcinomas of the salivary glands and were clinically without evidence of disease at 5 years of follow-up.
  • The crude rates of late recurrence by histologic subtype were adenoid cystic carcinoma (26%), mixed malignant tumor (25%), mucoepidermoid carcinoma (17%), adenocarcinoma (10%), and acinic cell carcinoma (8%).
  • CONCLUSIONS: A significant proportion of patients who are presumed to be cured of their disease at 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrence with additional follow-up.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Salivary Gland Neoplasms / mortality

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18008358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Monteiro LS, Bento MJ, Palmeira C, Lopes C: Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med; 2009 Jul;38(6):508-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours.
  • OBJECTIVE: The aim of this study was to determine epidermal growth factor receptor (EGFR) expression in malignant salivary gland tumours and its possible relationships with clinical and morphological findings, disease course and prognosis.
  • PATIENTS AND METHODS: The study sample comprised 88 patients diagnosed and treated for primary malignant salivary gland tumours between January 1992 and December 2002.
  • CONCLUSION: EGFR is not a useful indicator of prognosis in malignant salivary gland tumours.
  • However, the EGFR expression in salivary gland cancers like adenocarcinomas, undifferentiated carcinomas, mucoepidermoid carcinomas or salivary duct carcinomas suggests that these tumours may be a candidate for therapy investigation directed at EGFR.
  • [MeSH-major] Receptor, Epidermal Growth Factor / analysis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Carcinoma / surgery. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Ductal / pathology. Carcinoma, Ductal / surgery. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / surgery. Cell Membrane / pathology. Cytoplasm / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery. Prognosis. Retrospective Studies. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317849.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


85. Kinnera VS, Mandyam KR, Chowhan AK, Nandyala R, Bobbidi VP, Vutukuru VR: Salivary duct carcinoma of parotid gland. J Oral Maxillofac Pathol; 2009 Jul;13(2):85-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary duct carcinoma of parotid gland.
  • Based on the fine needle aspiration cytology report of adenocarcinoma not otherwise specified, superficial parotidectomy was performed, which showed the features of salivary duct carcinoma by histopathological examination.
  • The smears were reviewed to identify the potential pitfalls in the cytological diagnosis of salivary duct carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Oct 25;93(5):344-50 [11668470.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):223-30 [8625227.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):242-7 [8712181.001]
  • [Cites] Cytopathology. 1996 Apr;7(2):141-4 [9074665.001]
  • [Cites] Diagn Cytopathol. 1997 Jun;16(6):526-30 [9181320.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):333-7 [9812225.001]
  • [Cites] Diagn Cytopathol. 1998 Aug;19(2):120-3 [9702490.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1389-96 [9850648.001]
  • (PMID = 21887008.001).
  • [ISSN] 0973-029X
  • [Journal-full-title] Journal of oral and maxillofacial pathology : JOMFP
  • [ISO-abbreviation] J Oral Maxillofac Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3162867
  • [Keywords] NOTNLM ; Fine needle aspiration cytology / parotid malignancy / salivary duct carcinoma
  •  go-up   go-down


86. Ide F, Mishima K, Tanaka A, Saito I, Kusama K: Mucinous adenocarcinoma of minor salivary glands: a high-grade malignancy prone to lymph node metastasis. Virchows Arch; 2009 Jan;454(1):55-60
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of minor salivary glands: a high-grade malignancy prone to lymph node metastasis.
  • Salivary gland mucinous adenocarcinoma (MAC) is a rarely encountered and poorly understood tumor.
  • Minor salivary gland MAC belongs to a high-grade category with a significant risk of local recurrence, lymph node metastasis, and fatal outcome.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Lip Neoplasms / diagnosis. Salivary Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):738-40 [12464900.001]
  • [Cites] Histopathology. 2005 Oct;47(4):436-7 [16178903.001]
  • [Cites] Dermatologica. 1985;171(5):362-5 [3908175.001]
  • [Cites] Oral Oncol. 2008 Feb;44(2):187-92 [17418612.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):89-93 [14707869.001]
  • [Cites] J Oral Pathol Med. 2007 Jul;36(6):371-6 [17559500.001]
  • [Cites] Oral Oncol. 2007 May;43(5):463-70 [16979373.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):764-82 [15897743.001]
  • [Cites] Pathologe. 1993 Jul;14(4):210-5 [7690135.001]
  • [Cites] Am J Dermatopathol. 2007 Dec;29(6):595-6 [18032965.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):198-200 [9176796.001]
  • [Cites] HNO. 2008 Feb;56(2):231-8 [18214402.001]
  • [Cites] Arch Dermatol. 1991 Apr;127(4):588-9 [2006893.001]
  • [Cites] J Oral Pathol Med. 2004 Jan;33(1):59-63 [14675143.001]
  • [Cites] J Oral Pathol Med. 2006 Oct;35(9):582-5 [16968242.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1385-94 [15578883.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Jun;25(3):196-8 [8872222.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1440-7 [8944036.001]
  • (PMID = 19037659.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / Receptors, Estrogen
  •  go-up   go-down


87. Ettl T, Kleinheinz J, Mehrotra R, Schwarz S, Reichert TE, Driemel O: The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case. Head Face Med; 2008;4:16
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case.
  • BACKGROUND: With the 2005 WHO classification of salivary gland tumours and its increasingly recognized diagnostic entities, the frequency of adenocarcinoma (NOS) has decreased significantly.
  • CASE PRESENTATION: This paper describes a fast growing adenocarcinoma (NOS), originating from the minor salivary glands of the left buccal mucosa with a rapid onset of multiple local and distant metastases, especially in the lung.
  • CONCLUSION: A rare case of an adenocarcinoma (NOS) of the minor salivary glands with a rapid development and an unfavourable clinical course is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Neoplasm Metastasis. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Cancer. 2001 Oct 25;93(5):330-6 [11668468.001]
  • [Cites] Lung Cancer. 2004 May;44(2):149-57 [15084379.001]
  • [Cites] Am J Surg. 1982 Oct;144(4):423-31 [7125074.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Laryngoscope. 1988 Jul;98(7):784-8 [3386387.001]
  • [Cites] Histopathology. 2007 Jul;51(1):26-32 [17593078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1385-94 [15578883.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103(3):308-13 [17197205.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):94-100 [17577550.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Jan;101(1):102-4 [1728879.001]
  • (PMID = 18667060.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  • [Other-IDs] NLM/ PMC2515301
  •  go-up   go-down


88. Gao P, Zhou GY, Song XR, Hou JX, Zhang CJ, Ma C: [The relationship of abnormal expression of cell glucoprotein with recurrence of pleomorphic adenoma in salivary gland]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2005 Apr;23(2):164-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship of abnormal expression of cell glucoprotein with recurrence of pleomorphic adenoma in salivary gland].
  • OBJECTIVE: To study the relationship of expression of mucin 1 and E-cadherin with recurrence of pleomorphic adenoma in salivary gland, and to investigate the signal to predict the recurrence potential of the tumor.
  • [MeSH-major] Adenoma, Pleomorphic / physiopathology. Cadherins / metabolism. Mucin-1 / metabolism. Salivary Gland Neoplasms / physiopathology
  • [MeSH-minor] Adenocarcinoma. Humans. Immunohistochemistry. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952635.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Mucin-1
  •  go-up   go-down


89. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.
  • The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.
  • Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.
  • Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


90. Kobayashi M, Hattori M, Miyamoto T, Kakinuma H, Watanabe J, Iwabuchi K, Nishimura Y, Jobo T, Kuramoto H: Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report. Acta Cytol; 2007 Nov-Dec;51(6):916-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report.
  • BACKGROUND: Clear cell adenocarcinoma (CCA) of the minor salivary gland accounts for < 1% of all tumors of the salivary gland.
  • CONCLUSION: Although CCA of the palate is extremely rare, an accurate cytologic diagnosis can be made if the characteristic findings of CCA, including BMS, are imaged.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Basement Membrane / pathology. Palatal Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077986.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


91. Eida S, Ohki M, Sumi M, Yamada T, Nakamura T: MR factor analysis: improved technology for the assessment of 2D dynamic structures of benign and malignant salivary gland tumors. J Magn Reson Imaging; 2008 Jun;27(6):1256-62
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR factor analysis: improved technology for the assessment of 2D dynamic structures of benign and malignant salivary gland tumors.
  • PURPOSE: To establish an MR factor analysis technique for two-dimensional (2D) MR dynamic structures of benign and malignant salivary gland tumors.
  • MATERIALS AND METHODS: Dynamic contrast-enhanced MRI using a surface coil was performed on 36 patients with benign (N = 24) or malignant (N = 12) salivary gland tumors.
  • RESULTS: The MR factor analysis technique allowed the pixel-to-pixel evaluation of the contrast enhancement kinetics of the salivary gland tumors.
  • The 2D distributions of the time-intensity curve (TIC) patterns correlated well with the histological features of the salivary gland tumors and allowed more detailed dynamic structures of the tumors compared with the results obtained by the conventional dynamic study analysis.
  • CONCLUSION: The proposed MR factor analysis would be clinically feasible to diagnose salivary gland tumors and tumor-like lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Image Processing, Computer-Assisted / methods. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Neoplasms, Complex and Mixed / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology
  • [MeSH-minor] Aged. Cohort Studies. Contrast Media / administration & dosage. Diagnosis, Differential. Factor Analysis, Statistical. Feasibility Studies. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc
  • (PMID = 18504743.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


92. Tavora F, Rassaei N, Shilo K, Foss RD, Galvin JR, Travis WD, Franks TJ: Occult primary parotid gland acinic cell adenocarcinoma presenting with extensive lung metastasis. Arch Pathol Lab Med; 2007 Jun;131(6):970-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult primary parotid gland acinic cell adenocarcinoma presenting with extensive lung metastasis.
  • Acinic cell adenocarcinoma is a malignant salivary gland neoplasm with a relatively low rate of lymphangitic spread to regional lymph nodes.
  • We encountered an unusual example of acinic cell adenocarcinoma that initially presented in the lung, whereas the primary parotid carcinoma, despite extensive clinical evaluation, only became apparent 1 year after initial diagnosis.
  • The histologic, immunohistochemical, and ultrastructural features of the tumor in the parotid gland and lung were similar.
  • This presentation is unique, showing that peripheral lung tumors of salivary gland type are likely to be metastatic, and careful clinical evaluation is warranted in establishing their primary site of origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550329.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


93. Ruíz-Godoy L, Suárez L, Mosqueda A, Meneses A: Polymorphous low-grade adenocarcinoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2007 Jan;12(1):E30-3
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of the parotid gland. Case report and review of the literature.
  • Polymorphous low-grade adenocarcinoma (PLGA) is difficult to diagnose both clinically and histologically due to its indolent presentation, and because of its morphological diversity that includes several microscopic patterns.
  • The aggressive biologic behavior seen in minor salivary glands as compared to major glands is apparently associated histologically to a predominance of the papillary pattern in the former.
  • Biologic behavior of PLGA in the major salivary glands is uncertain, as some cases have developed recurrences and metastases independently of the presence of a papillary pattern.
  • A case of PLGA originated de novo in parotid gland is presented a 60 year-old male, treatment was surgically excised through superficial parotidectomy and to postoperative radiotherapy (46 Gy).
  • Forty-eight months later the patient is alive with no signs of recurrence, as well as a review of the literature, with particular emphasis in its differential diagnosis and biological behavior.
  • [MeSH-major] Adenocarcinoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195824.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 18
  •  go-up   go-down


94. Ansari MH: Salivary gland tumors in an Iranian population: a retrospective study of 130 cases. J Oral Maxillofac Surg; 2007 Nov;65(11):2187-94
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors in an Iranian population: a retrospective study of 130 cases.
  • PURPOSE: Tumors of the salivary glands are uncommon, comprising 3% to 10% of head and neck neoplasia.
  • PATIENTS AND METHODS: The medical records and case notes of all patients with histologically confirmed salivary gland tumors were reviewed retrospectively from February 1984 to March 2003.
  • Tumors were localized in the parotid gland (63%; n = 82), the submandibular gland (23%; n = 30), and in the minor salivary glands (14%; n = 18).
  • Among malignant tumors, mucoepidermoid carcinoma was the most frequent (11.5%; n = 15), followed by adenocarcinoma (10%; n = 13).
  • CONCLUSION: Between benign and malignant salivary gland tumors, frequency of pleomorphic adenoma and mucoepidermoid carcinoma was in keeping with studies reported previously.
  • In other salivary gland tumors, however, diversity was obvious and showed significant difference, requiring further studies.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Carcinoma, Mucoepidermoid / epidemiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Iran / epidemiology. Male. Middle Aged. Neoadjuvant Therapy. Parotid Neoplasms / epidemiology. Retrospective Studies. Salivary Glands, Minor / pathology. Submandibular Gland Neoplasms / epidemiology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954313.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Daniel E, McGuirt WF Sr: Neck masses secondary to heterotopic salivary gland tissue: a 25-year experience. Am J Otolaryngol; 2005 Mar-Apr;26(2):96-100
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neck masses secondary to heterotopic salivary gland tissue: a 25-year experience.
  • OBJECTIVES: The aim of this study is to review salivary tumors arising from heterotopic salivary inclusions in the periparotid and cervical lymph nodal tissues over a 25-year span.
  • METHODS: A retrospective chart review revealed 24 patients with asymptomatic neck masses treated between 1976 and 2001, whose pathology demonstrated heterotopic salivary tissue or neoplasms arising from heterotopic salivary tissue.
  • RESULTS: Nine cases were benign periparotid lymph nodes with heterotopic salivary inclusions, 3 of which had multimodal involvement.
  • Fifteen cases of heterotopic salivary tumors were identified.
  • Malignant tumors included mucoepidermoid (3), acinic cell (2), and adenocarcinoma (1).
  • CONCLUSIONS: Heterotopic salivary tissue in periparotid and upper cervical nodes is a more common occurrence than historically recognized.
  • Tumorigenic changes arise from heterotopic nodal inclusions, and although infrequent, should be considered in the differential diagnosis for isolated neck/periparotid masses and parotid Warthin's tumor.
  • Suggested management, after a thorough clinical exam/needle aspiration biopsy, includes an imaging survey of the parotid gland and neck lymphatics with an appropriate resection to include a simple excision, parotidectomy, neck dissection, and/or irradiation as indicated.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Choristoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742261.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Bastaki J, Summersgill K: Signet-ring cell (mucin-producing) adenocarcinoma of minor salivary glands: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct;110(4):e33-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell (mucin-producing) adenocarcinoma of minor salivary glands: report of a case.
  • Salivary gland tumors account for a significant group of head and neck neoplasms.
  • Signet-ring cell (mucin-producing) adenocarcinoma of minor salivary glands was described by Ghannoum and Freedman in 2004.
  • We report a case of this extremely rare minor salivary gland neoplasm in an 18-year-old male.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20868985.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. McNamara ZJ, Batstone M, Farah CS: Carcinoma ex pleomorphic adenoma in a minor salivary gland of the upper lip. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Nov;108(5):e51-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex pleomorphic adenoma in a minor salivary gland of the upper lip.
  • We present an exceedingly rare case of carcinoma ex pleomorphic adenoma (CXPA) arising in a minor salivary gland of the upper lip.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836713.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Targa-Stramandinoli R, Torres-Pereira C, Piazzetta CM, Giovanini AF, Amenábar JM: [Minor salivary gland tumours: a 10-year study]. Acta Otorrinolaringol Esp; 2009 May-Jun;60(3):199-201
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minor salivary gland tumours: a 10-year study].
  • [Transliterated title] Neoplasias de glándulas salivales menores: estudio de 10 años.
  • Salivary gland tumours represent between 2 % and 6.5 %, approximately, of all head and neck tumours.
  • The aim of this paper was to identify the frequency of minor salivary gland tumours among patients in the Oral Medicine Clinic of the Federal University of Paraná during the period from 1997 to 2007.
  • Fourteen cases of salivary gland tumours were found, of which 7 were benign and 7 malignant.
  • By histological type, 50 % of the lesions were characterized as pleomorphic adenoma, 28.6 % mucoepidermoid carcinoma, 14.3 % cystic adenoid carcinoma and 7.1 % as polymorphous adenocarcinoma.
  • These findings suggest that salivary gland tumours have a low incidence in the population and that the pleomorphic adenoma is the most common type of tumour, followed by mucoepidermoid carcinoma.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology. Salivary Glands, Minor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558907.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Yamate J, Yamamoto E, Nabe M, Kuwamura M, Fujita D, Sasai H: Spontaneous adenocarcinoma immunoreactive to cyclooxygenase-2 and transforming growth factor-beta1 in the buccal salivary gland of a Richardson's ground squirrel (Spermophilus richardsonii). Exp Anim; 2007 Oct;56(5):379-84
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous adenocarcinoma immunoreactive to cyclooxygenase-2 and transforming growth factor-beta1 in the buccal salivary gland of a Richardson's ground squirrel (Spermophilus richardsonii).
  • This tumor was diagnosed as an adenocarcinoma arising from the buccal gland, the first case reported in the ground squirrel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075199.001).
  • [ISSN] 1341-1357
  • [Journal-full-title] Experimental animals
  • [ISO-abbreviation] Exp. Anim.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


100. Adeyemi BF, Kolude BM, Akang EE, Lawoyin JO: A study of the utility of silver nucleolar organizer regions in categorization and prognosis of salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct;102(4):513-20
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of the utility of silver nucleolar organizer regions in categorization and prognosis of salivary gland tumors.
  • BACKGROUND: this study aimed at assessing the utility of silver nucleolar organizer region (AgNOR) staining in categorization and prognostication of salivary gland tumors.
  • METHODS: Twenty-seven malignant salivary gland tumors, 16 benign neoplasms, and 6 chronic sialadenitis lesions were stained using the technique described by Ploton et al. (1986).
  • In addition, no correlation was found between mean AgNOR counts and the clinical course of malignant or benign salivary gland neoplasms.
  • CONCLUSION: Our results suggest that AgNOR staining is useful for distinguishing benign from malignant lesions, but is neither helpful for discriminating between histological types and grades of malignant neoplasms, nor prognostication of malignant salivary gland neoplasms.
  • [MeSH-major] Nucleolus Organizer Region / pathology. Salivary Gland Neoplasms / pathology. Silver Staining
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Sialadenitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Future Oncol. 2007 Feb;3(1):49-53 [17280501.001]
  • (PMID = 16997120.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement